HIV Incidence Among Pregnant and Nonpregnant Women in the FACTS-001 Trial: Implications for HIV Prevention, Especially PrEP Use

Supplemental Digital Content is Available in the Text. Background: During pregnancy and postpartum period, the sexual behaviors of women and their partners change in ways that may either increase or reduce HIV risks. Pregnant women are a priority population for reducing both horizontal and vertical HIV transmission. Setting: Nine sites in 4 South African provinces. Methods: Women aged 18–30 years were randomized to receive pericoital tenofovir 1% gel or placebo gel and required to use reliable modern contraception. We compared HIV incidence in women before, during, and after pregnancy and used multivariate Cox Proportional hazards models to compare HIV incidence by pregnancy status. Results: Rates of pregnancy were 7.1 per 100 woman-years (95% confidence interval [CI]: 6.3 to 8.1) and highest in those who reported oral contraceptive use (25.1 per 100 woman-years; adjusted hazard ratio 22.97 higher than other women; 95% CI: 5.0 to 105.4) or had 2 children. Birth outcomes were similar between trial arms, with 59.8% having full-term live births. No difference was detected in incident HIV during pregnancy compared with nonpregnant women (2.1 versus 4.3%; hazard ratio = 0.56, 95% CI: 0.14 to 2.26). Sexual activity was low in pregnancy and the early postpartum period, as was consistent condom use. Conclusions: Pregnancy incidence was high despite trial participation being contingent on contraceptive use. We found no evidence that rates of HIV acquisition were elevated in pregnancy when compared with those in nonpregnant women. Risks from reductions in condom use may be offset by reduced sexual activity. Nevertheless, high HIV incidence in both pregnant and nonpregnant women supports consideration of introducing antiretroviral-containing pre-exposure prophylaxis for pregnant and nonpregnant women in high HIV prevalence settings.

[1]  A. van der Straten,et al.  Influences on willingness to use vaginal or oral HIV PrEP during pregnancy and breastfeeding in Africa: the multisite MAMMA study , 2020, Journal of the International AIDS Society.

[2]  B. Chi,et al.  Emerging evidence from a systematic review of safety of pre‐exposure prophylaxis for pregnant and postpartum women: where are we now and where are we heading? , 2020, Journal of the International AIDS Society.

[3]  Fujie Xu,et al.  Guides Concerning Tenofovir Exposure via Breastfeeding: A Comparison of Drug Dosages by Developmental Stage. , 2019, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[4]  H. Rees,et al.  Inclusion of pregnant women in antiretroviral drug research: what is needed to move forwards? , 2019, Journal of the International AIDS Society.

[5]  L. Myer,et al.  Prevalence and correlates of sexually transmitted infections in pregnancy in HIV-infected and- uninfected women in Cape Town, South Africa , 2019, PloS one.

[6]  R. Chou,et al.  Pre-Exposure Prophylaxis for the Prevention of HIV Infection: A Systematic Review for the U.S. Preventive Services Task Force , 2019 .

[7]  A. Moll,et al.  Perceptions of HIV Preexposure Prophylaxis Among Young Pregnant Women from Rural KwaZulu-Natal, South Africa. , 2019, AIDS patient care and STDs.

[8]  S. Delany-Moretlwe,et al.  Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial. , 2018, The Lancet. Infectious diseases.

[9]  J. Baeten,et al.  HIV-Uninfected Kenyan Adolescent and Young Women Share Perspectives on Using Preexposure Prophylaxis During Pregnancy. , 2018, AIDS patient care and STDs.

[10]  J. Baeten,et al.  Increased Risk of HIV Acquisition Among Women Throughout Pregnancy and During the Postpartum Period: A Prospective Per-Coital-Act Analysis Among Women With HIV-Infected Partners , 2018, The Journal of infectious diseases.

[11]  K. Wall,et al.  A Systematic Review of the Current Status of Safer Conception Strategies for HIV Affected Heterosexual Couples in Sub-Saharan Africa , 2018, AIDS and Behavior.

[12]  J. Baeten,et al.  Pregnancy outcomes and infant growth among babies with in-utero exposure to tenofovir-based preexposure prophylaxis for HIV prevention. , 2018, AIDS.

[13]  H. Rees,et al.  Lessons learnt from the introduction of the contraceptive implant in South Africa , 2017, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[14]  L. Myer,et al.  Delivering preexposure prophylaxis to pregnant and breastfeeding women in Sub-Saharan Africa: the implementation science frontier. , 2017, AIDS.

[15]  G. Guyatt,et al.  Antiretroviral therapy in pregnant women living with HIV: a clinical practice guideline , 2017, British Medical Journal.

[16]  N. Ford,et al.  Safety of Tenofovir Disoproxil Fumarate–Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis , 2017, Journal of acquired immune deficiency syndromes.

[17]  A. Vandormael,et al.  Incident HIV during pregnancy and early postpartum period: a population-based cohort study in a rural area in KwaZulu-Natal, South Africa , 2017, BMC Pregnancy and Childbirth.

[18]  J. Baeten,et al.  Safety of oral tenofovir disoproxil fumarate-based HIV pre-exposure prophylaxis use in lactating HIV-uninfected women , 2017, Expert opinion on drug safety.

[19]  K. Bunge,et al.  Contraceptive Use and Pregnancy Incidence Among Women Participating in an HIV Prevention Trial. , 2017, Journal of women's health.

[20]  L. Mofenson,et al.  Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding , 2017, AIDS.

[21]  B. Chi,et al.  Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention. , 2016, The New England journal of medicine.

[22]  E. Delaporte,et al.  Getting pregnant in HIV clinical trials: women’s choice and safety needs. The experience from the ANRS12169-2LADY and ANRS12286-MOBIDIP trials , 2016, HIV clinical trials.

[23]  N. Shaffer,et al.  Impact of Maternal HIV Seroconversion during Pregnancy on Early Mother to Child Transmission of HIV (MTCT) Measured at 4-8 Weeks Postpartum in South Africa 2011-2012: A National Population-Based Evaluation , 2015, PloS one.

[24]  N. Angelopoulos,et al.  The vaginal microbiome during pregnancy and the postpartum period in a European population , 2015, Scientific Reports.

[25]  Douglas J. Taylor,et al.  Pregnancy and Contraceptive Use Among Women Participating in the FEM-PrEP Trial , 2015, Journal of acquired immune deficiency syndromes.

[26]  David R. Holtgrave,et al.  HIV prevention in clinical care settings: 2014 recommendations of the International Antiviral Society-USA Panel. , 2014, JAMA.

[27]  C. Morrison,et al.  Cervical Inflammation and Immunity Associated With Hormonal Contraception, Pregnancy, and HIV-1 Seroconversion , 2014, Journal of acquired immune deficiency syndromes.

[28]  Alison L. Drake,et al.  Incident HIV during Pregnancy and Postpartum and Risk of Mother-to-Child HIV Transmission: A Systematic Review and Meta-Analysis , 2014, PLoS medicine.

[29]  S. Gregson,et al.  Is the Risk of HIV Acquisition Increased during and Immediately after Pregnancy? A Secondary Analysis of Pooled HIV Community-Based Studies from the ALPHA Network , 2013, PloS one.

[30]  Katrien Fransen,et al.  Preexposure prophylaxis for HIV infection among African women. , 2012, The New England journal of medicine.

[31]  W. Miller,et al.  High HIV Incidence and Sexual Behavior Change among Pregnant Women in Lilongwe, Malawi: Implications for the Risk of HIV Acquisition , 2012, PloS one.

[32]  S. Luchters,et al.  Changes in sexual behaviour among HIV-infected women in west and east Africa in the first 24 months after delivery , 2012, AIDS.

[33]  S. Karim,et al.  Contraceptive Choices, Pregnancy Rates, and Outcomes in a Microbicide Trial , 2011, Obstetrics and gynecology.

[34]  J. Baeten,et al.  Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1-serodiscordant couples , 2011, AIDS.

[35]  L. Mofenson,et al.  Pharmacokinetics and Safety of Single-Dose Tenofovir Disoproxil Fumarate and Emtricitabine in HIV-1-Infected Pregnant Women and Their Infants , 2011, Antimicrobial Agents and Chemotherapy.

[36]  N. El-Badri,et al.  ORIGINAL ARTICLE: Suppression of Natural Killer Cell Cytotoxicity in Postpartum Women , 2010, American journal of reproductive immunology.

[37]  James Y. Dai,et al.  Pregnancy, Contraceptive Use, and HIV Acquisition in HPTN 039: Relevance for HIV Prevention Trials Among African Women , 2009, Journal of acquired immune deficiency syndromes.

[38]  D. McIntire,et al.  The Effect of Progesterone Levels and Pregnancy on HIV-1 Coreceptor Expression , 2009, Reproductive Sciences.

[39]  C. Morrison,et al.  Pregnancy and the risk of HIV-1 acquisition among women in Uganda and Zimbabwe , 2007, AIDS.

[40]  G. Doncel,et al.  In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. , 2005, AIDS research and human retroviruses.

[41]  N. Sewankambo,et al.  Increased risk of incident HIV during pregnancy in Rakai, Uganda: a prospective study , 2005, The Lancet.

[42]  H. Brou,et al.  Resumption of Sexual Relations Following Childbirth: Norms, Practices and Reproductive Health Issues in Abidjan, Côte d'Ivoire , 2005, Reproductive health matters.

[43]  G. Chrousos,et al.  IL-12, TNF-alpha, and hormonal changes during late pregnancy and early postpartum: implications for autoimmune disease activity during these times. , 2001, The Journal of clinical endocrinology and metabolism.

[44]  J. Trussell Contraceptive efficacy. , 1995, Archives of dermatology.